PepGen Alternatives & Competitors
12 companies similar to PepGen — Better Technology. Better Delivery. Developing a new generation of disease-modif...
Companies similar to PepGen
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
Avidity Biosciences, Inc.
At Avidity, we are developing a new class of oligonucleotide-based therapies.
San Diego, United States
Entrada Therapeutics
Innovating to transform the treatment of serious diseases through establishing a new class...
Boston, United States
Prevail Therapeutics
Wholly owned subsidiary of Eli Lilly and Company
New York, United States
Track all PepGen competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
AusperBio
Transforming Patient Lives For a Better Tomorrow
San Mateo, United States
Solid Biosciences
#TogetherWeAreSolid
Boston, United States
Ascidian Therapeutics
Rewriting RNA
Boston, United States
Locanabio, Inc.
Creating RNA-targeting gene therapies to treat devastating diseases
San Diego, United States
ARTHEx Biotech
Developing microRNA modulators for diseases with unmet medical needs
Paterna, Spain
Scenic Biotech
Evolution-inspired medicine
Amsterdam, The Netherland...
Gain Therapeutics
Unfolding the next generation of allosteric small molecule therapies to meet patient needs...
Bethesda, United States
Neurogene Inc.
Reimagining the future for rare neurological diseases
New York, United States
About PepGen
PepGen, founded in 2018, is a burgeoning player in the Biotechnology industry, headquartered in the United States. The company is on a mission to revolutionize treatment options for genetic neuromuscular and neurological disorders through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. PepGen's approa...
development of disease-modifying therapies, conducting clinical trials, scientific research publications
patients with genetic neuromuscular diseases, patients with neurological diseases, medical professionals, healthcare providers
Enhanced Delivery Oligonucleotide (EDO) Platform, Disease-modifying Therapies, Genetic Neuromuscular Disorders, Neurological Disorders, Nucleic Acid Therapeutics, Antisense Oligonucleotides, Conjugate Therapeutics, Drug Delivery Technologies, Therapeutics Development, Proprietary Drug Platforms, Genetic Disorders, Neuromuscular Diseases, Precision Medicine, Innovative Drug Solutions
B2B, D2C, B2D
Licensing, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches PepGen and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at PepGen on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
